Viramal is an emerging specialty pharmaceutical company focused on the development of global therapeutics that improve the quality of women’s health worldwide. The Company is developing innovative products that target unmet therapeutic areas through the use of its unique pharmaceutical delivery platforms and technologies. These new therapies are anticipated to provide greater efficacy and patient acceptability, with far fewer side effects. Viramal’s robust women’s health clinical development pipeline includes treatments for endometriosis and fertility, menopausal hormone therapy, contraception, sexual health and other potential indications.

Viramal produces a step change in these existing products, as well as develops innovative products that target unmet therapeutic areas, by leveraging novel platform delivery technologies that offer greater safety, efficacy and patient acceptability with far fewer side effects.

Our robust women’s health clinical development pipeline includes treatments for fertility, menopausal hormone therapy, contraception and sexual health. In addition, the Company’s only male product, TestoCream (transdermal delivery of testosterone), has shown 81% success in a partially completed Phase III study. Combined, these products represent a market opportunity in excess of $20 billion globally. More information on the Company’s product portfolio can be found here.

Several of the Company’s late-stage products are available for out-licensing. For enquiries, please access the “Contact Us” portion of the website.